New perspectives in the natural history of multiple sclerosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Neurology

• Publication date

  2010-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0b013e3181e3973fPMID 20548045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The natural history of secondary progressive multiple sclerosis

  2010cited by this paper
• Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis

  2009cited by this paper
• Impact of multiple sclerosis relapses on progression diminishes with time

  2009cited by this paper
• Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities

  2009cited by this paper
• HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis.

  2009cited by this paper
• Cognitive impairment and structural brain damage in benign multiple sclerosis

  2008cited by this paper
• CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients

  2008cited by this paper
• Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease

  2008cited by this paper
• Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

  2008cited by this paper
• Natural history of multiple sclerosis in a population‐based cohort

  2008cited by this paper
• Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study

  2008cited by this paper
• Relapses in multiple sclerosis are age- and time-dependent

  2008cited by this paper
• Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis.

  2008cited by this paper
• Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway

  2008cited by this paper
• Mortality in multiple sclerosis: a review

  2008cited by this paper
• Contribution of relapses to disability in multiple sclerosis

  2008cited by this paper
• Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis

  2008cited by this paper
• Contribution of relapses to disability in multiple sclerosis

  2008cited by this paper
• Natural history of secondary-progressive multiple sclerosis

  2008cited by this paper
• Factors associated with the risk of secondary progression in multiple sclerosis

  2008cited by this paper
• Progression in familial and nonfamilial MS

  2008cited by this paper
• Temporal trends in the incidence of multiple sclerosis

  2008cited by this paper
• Clinical characteristics of patients with late-onset multiple sclerosis

  2008cited by this paper
• Timing of birth and disease progression in multiple sclerosis

  2008cited by this paper
• An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus

  2007cited by this paper
• A timing-of-birth effect on multiple sclerosis clinical phenotype

  2007cited by this paper
• Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France

  2007cited by this paper
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007cited by this paper
• Neurology®

  2007cited by this paper
• Age at onset determines the occurrence of the progressive phase of multiple sclerosis

  2007cited by this paper
• Predictive value of clinical characteristics for ‘benign’ multiple sclerosis

  2007cited by this paper
• Longitudinal follow-up of “benign” multiple sclerosis at 20 years

  2007cited by this paper
• Long-term prognosis of multiple sclerosis in Australia.

  2007cited by this paper
• Natural history of multiple sclerosis with childhood onset.

  2007cited by this paper
• Progression in multiple sclerosis: further evidence of an age dependent process.

  2007cited by this paper
• Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.

  2006cited by this paper
• Familial effects on the clinical course of multiple sclerosis

  2006cited by this paper
• Age at disability milestones in multiple sclerosis.

  2006cited by this paper
• Natural history of multiple sclerosis: a unifying concept.

  2006cited by this paper
• The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

  2006cited by this paper
• Is late-onset multiple sclerosis associated with a worse outcome?

  2006cited by this paper
• Disability progression in multiple sclerosis is slower than previously reported

  2006cited by this paper
• The natural history of primary progressive MS in British Columbia, Canada

  2005cited by this paper
• McAlpine's Multiple Sclerosis

  2005cited by this paper
• Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study

  2004cited by this paper
• Disability profile of MS did not change over 10 years in a population-based prevalence cohort

  2004cited by this paper
• Trends in survival and cause of death in Danish patients with multiple sclerosis.

  2004cited by this paper
• Effect of relapses on development of residual deficit in multiple sclerosis

  2003cited by this paper
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

  2003cited by this paper
• Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.

  2003cited by this paper
• Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis

  2003cited by this paper
• Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension

  2001cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

  1999cited by this paper
• Survival and predictors of disability in Turkish MS patients

  1998cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Natural history of multiple sclerosis

  1994cited by this paper
• Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

  1993cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

  1991cited by this paper
• The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

  1989cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

  1989cited by this paper
• Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study

  1988cited by this paper
• General right censoring and its impact on the analysis of survival data.

  1979cited by this paper
• General right censoring and its impact on the analysis of survival data.

  1979cited by this paper

• Assessing validity and reliability of the Benefit Finding Scale in Italian people with multiple sclerosis and their caregivers

  2026cites this paper
• Advancing multiple sclerosis management in older adults

  2025cites this paper
• Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis

  2025cites this paper
• Healthcare use is elevated two decades before a first demyelinating event and differs by age and sex

  2025cites this paper
• Multiple sclerosis from onset to secondary progression: a 30-year Italian register study

  2025cites this paper
• Benign multiple sclerosis and long-term outcomes after 30 years

  2025cites this paper
• Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifying therapies: Achievements and opportunities.

  2024cites this paper
• Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression

  2024cites this paper
• Strategic De-escalation of Disease-Modifying Therapies in Elderly Patients: Approaches and Considerations

  2024cites this paper
• Early clinical predictors of long-term disability progression in patients with multiple sclerosis

  2024cites this paper
• Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?

  2023cites this paper
• The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis.

  2023cites this paper
• A mixture model for differentiating longitudinal courses of multiple sclerosis.

  2023cites this paper
• Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study

  2023cites this paper
• Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

  2023cites this paper
• Disability and prognostic factors of MS severity: An Algerian cohort study

  2023cites this paper
• Influence of Transcranial Direct Current Stimulation and Exercise on Fatigue and Quality of Life in Multiple Sclerosis

  2022cites this paper
• Baseline retinal nerve fiber layer thickness as a predictor of multiple sclerosis progression: New insights from the FREEDOMS II study

  2022cites this paper
• Progressive Multiple Sclerosis

  2022cites this paper
• Sex and age differences in the Multiple Sclerosis prodrome

  2022cites this paper
• Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes

  2022influential citation
• Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy

  2022cites this paper
• Escalation vs. Early Intense Therapy in Multiple Sclerosis

  2022cites this paper
• To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis

  2022cites this paper
• Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival

  2022cites this paper
• Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population

  2022cites this paper
• Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

  2022cites this paper
• Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: a multicenter cross-sectional study.

  2021cites this paper
• Serum Anti-oligodendrocyte Autoantibodies in Patients With Multiple Sclerosis Detected by a Tissue-Based Immunofluorescence Assay

  2021cites this paper
• Estimation and discussion of prognosis in neurologic practice. Communication issues with patient with neurological disease

  2021cites this paper
• Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment

  2021cites this paper
• Diversity of Reactive Astrogliosis in CNS Pathology: Heterogeneity or Plasticity?

  2021cites this paper
• A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile

  2021cites this paper
• Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal.

  2021cites this paper
• Contribution of common risk variants to multiple sclerosis in Orkney and Shetland

  2021cites this paper
• Apparent changes in the epidemiology and severity of multiple sclerosis

  2021cites this paper
• Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course

  2021cites this paper
• Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study

  2021cites this paper
• Treatment of Spasticity Due to Multiple Sclerosis with Sativex®: Who Benefits Most? Three Case Reports

  2021cites this paper
• Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada

  2021cites this paper
• Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.

  2021cites this paper
• Prognostic value of odor identification impairment in multiple sclerosis: 10-Years follow-up.

  2020cites this paper
• Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.

  2020cites this paper
• Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.

  2020cites this paper
• A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis

  2020cites this paper
• Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool

  2020cites this paper
• Generating Digital Twins with Multiple Sclerosis Using Probabilistic Neural Networks

  2020cites this paper
• The genetics of multiple sclerosis in the Northern Isles of Scotland

  2020influential citation
• Clinically isolated syndrome, oligoclonal bands and multiple sclerosis

  2020cites this paper
• Predictive medicine in multiple sclerosis: A systematic review.

  2020cites this paper
• Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis

  2020cites this paper
• Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.

  2020cites this paper
• Accurate classification of secondary progression in multiple sclerosis using a decision tree

  2020cites this paper
• New applications for independent activities of daily living in measuring disability in multiple sclerosis

  2020cites this paper
• Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment.

  2020cites this paper
• Selected Disorders of the Nervous System

  2020cites this paper
• Multiple Sclerosis

  2020cites this paper
• Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis

  2020influential citation
• The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis

  2019cites this paper
• Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

  2019cites this paper
• Drug Treatment of Clinically Isolated Syndrome

  2019cites this paper
• Pharmacoeconomics of synthetic therapies for multiple sclerosis

  2019cites this paper
• The MSBase registry: Informing clinical practice

  2019cites this paper
• Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis

  2019cites this paper
• Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

  2019cites this paper
• Relating Treatment Effect on Relapses with Disability Worsening in Multiple Sclerosis Patients: Age Matters

  2019influential citation
• Multiple sclerosis: effect of beta interferon treatment on survival.

  2019cites this paper
• Causes that Contribute to the Excess Mortality Risk in Multiple Sclerosis: A Population-Based Study

  2019cites this paper
• Prodrome in relapsing‐remitting and primary progressive multiple sclerosis

  2019cites this paper
• To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.

  2019cites this paper
• Socioeconomic status and disability progression in multiple sclerosis

  2019cites this paper
• Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis.

  2019cites this paper
• Treatment strategies in multiple sclerosis : current and future practice considerations

  2019cites this paper
• Histoire naturelle de la sclérose en plaques

  2019cites this paper
• Psychiatric comorbidity is associated with disability progression in multiple sclerosis

  2018cites this paper
• Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study

  2018cites this paper
• Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

  2018cites this paper
• SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts

  2018cites this paper
• Epidemiology of hip fracture in nursing home residents with multiple sclerosis.

  2018cites this paper
• Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme

  2018cites this paper
• Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis

  2018cites this paper
• Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  2018cites this paper
• Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.

  2018cites this paper
• Characterization of annual disease progression of multiple sclerosis patients: A population-based study

  2018cites this paper
• Lietuvos sveikatos mokslų universitetas

  2018cites this paper
• Multiple Sclerosis: Mechanisms and Immunotherapy

  2018cites this paper
• Effects of physical comorbidities on disability progression in multiple sclerosis

  2018cites this paper
• Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients

  2018cites this paper
• Clinical follow‐up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real‐life cohort study

  2018cites this paper
• Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis.

  2018cites this paper
• Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

  2018cites this paper
• The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset.

  2018cites this paper
• Predicting risk of secondary progression in multiple sclerosis: A nomogram

  2018cites this paper
• Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations

  2018cites this paper
• Promoting Resilience in Individuals Aging With Multiple Sclerosis: Results From a Pilot Randomized Controlled Trial

  2018cites this paper
• Natural Course of Clinically Isolated Syndrome: A Longitudinal Analysis Using a Markov Model

  2018cites this paper
• Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

  2018cites this paper
• Ethnicity and prevalence of multiple sclerosis in east London

  2017cites this paper
• Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study

  2017cites this paper
• Disability progression in aggressive multiple sclerosis

  2017cites this paper